ArticleLeukemia2020
Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms.
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Molecular diagnosis of inherited platelet disorder via a targeted whole-exome virtual gene panel: a 5-year institutional experience.Research and practice in thrombosis and haemostasis · 2026Article
- RUNX1-FPDMM in families with mild thrombocytopenia and platelet function anomalies: a case series.Frontiers in medicine · 2025Article
- Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.American journal of hematology · 2024Review
- Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41.Blood advances · 2023Article
- Stagnation in quality of next-generation sequencing assays for the diagnosis of hereditary hematopoietic malignancies.Journal of genetic counseling · 2023Article
- Molecular genetics and management of world health organization defined atypical chronic myeloid leukemia.Annals of hematology · 2023Article
- Germline and somatic drivers in inherited hematologic malignancies.Frontiers in oncology · 2023Review
- Clonal hematopoiesis in patients with ANKRD26 or ETV6 germline mutations.Blood advances · 2022Article
- Beyond PathogenicCancers · 2022Review
- How I diagnose and treat chronic myelomonocytic leukemia.Haematologica · 2022Article
- Tumor necrosis factor‑related apoptosis‑inducing ligand is a novel transcriptional target of runt‑related transcription factor 1.International journal of oncology · 2022Article
- The Emerging Role of Hematopathologists and Molecular Pathologists in Detection, Monitoring, and Management of Myeloid Neoplasms with Germline Predisposition.Current hematologic malignancy reports · 2021Review
- Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.Hematology. American Society of Hematology. Education Program · 2020Review
- Germline mutations: many roles in leukemogenesis.Current opinion in hematology · 2020Review
- Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies.Current hematologic malignancy reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
32060405What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.